Human Disease Model Report: muscular dystrophy, DAG1-related

General Information

Name

muscular dystrophy, DAG1-related

FlyBase ID

FBhh0000192

Disease Ontology Term

muscular dystrophy

Parent Disease

OMIM

Overview

In humans, multiple genes have been implicated in muscular dystrophy; in addition, in most cases, any specific gene is implicated in multiple forms of the disease. This report describes fly models of muscular dystrophy related to the gene dystroglycan 1, also known as dystrophin-associated glycoprotein (DAG1); the dystrophin-glycoprotein complex links the extracellular matrix and the cytoskeleton in the skeletal muscle. The DAG1 gene is implicated in several forms of muscular dystrophy, see MIM:128239 (see also FBhh0000207, FBhh0000208). There is a single fly ortholog, Dmel\Dg, for which classical hypomorphic alleles, RNAi-targeting constructs, and alleles caused by insertional mutagenesis have been generated.

A UAS construct of the wild-type human Hsap\DAG1 gene has been introduced into flies; heterologous rescue has not been tested.

The more severe hypomorphic alleles of Dmel\Dg, when homozygous, are lethal in late larval stage; larval muscle phenotypes have been described. Precise levels of Dg appear to be critical: lower levels slow down neuronal stem cell division, while higher levels accelerate proliferation and perturb neuron differentiation. Animals with altered Dg levels, either loss- and gain-of-function mutants, exhibit a cobblestone brain phenotype (a type of lissencephaly). Adult phenotypes have allowed characterization of genetic interactions. Physical interactions of the Dg protein product have been described; see below and in the FlyBase gene report for Dg.

MicroRNAs of the mir-310 cluster (mir-310, mir-311, mir-312 and mir-313) bind to the extended 3'UTR of longer Dmel\Dg transcripts. Animals carrying a small deletion that removes all 4 genes of the mir-310 cluster exhibit a cobblestone brain phenotype.

[updated May 2019 by FlyBase; FBrf0222196]

Disease Summary Information

Disease Summary: muscular dystrophy, DAG1-related

OMIM report

Human gene(s) implicated

Symptoms and phenotype

Congenital muscular dystrophy (CMD) is a clinically and genetically heterogeneous group of inherited muscle disorders. Muscle weakness typically presents from birth to early infancy. Affected infants typically appear "floppy" with low muscle tone and poor spontaneous movements. Affected children may present with delay or arrest of gross motor development together with joint and/or spinal rigidity. [Gene Reviews, Congenital Muscular Dystrophy Overview; 2019.05.31]

(FlyBase Curators, 2013-)

Genetics

A form of limb-girdle muscular dystrophy-dystroglycanopathy (type C9; MDDGC9) is caused by homozygous mutation in the gene encoding alpha-dystroglycan (DAG1). A second more severe type of muscular dystrophy (MIM:616538) is also associated with mutations in the DAG1 gene. [from MIM:613818, MIM:128239; 2016.03.11]

(OMIM, 2013-)

Cellular phenotype and pathology

The brain malformation cobblestone lissencephaly (type II lissencephaly) is observed in severe forms of α-dystroglycanopathy (Yamamoto, et al., 2014; pubmed:25403635).

(FlyBase Curators, 2013-)

Molecular information

Dystroglycan is a central component of the dystrophin-glycoprotein complex that links the extracellular matrix and the cytoskeleton in the skeletal muscle. [from Gene Cards, DAG1, 2016.03.25]

(FlyBase Curators, 2013-)

External links

Gene2Function (human gene): DAG1
Gene Cards: DAG1
GeneReviews, NCBI Bookshelf: Congenital Muscular Dystrophy Overview
MedlinePlus (condition): Limb-girdle muscular dystrophy
MedlinePlus (gene): DAG1
MARRVEL (human gene): DAG1
NCBI MedGen: Limb-girdle muscular dystrophy-dystroglycanopathy, type C9 (MDDGC9)
NCBI MedGen: Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 9 (MDDGA9)
NCBI (Entrez) gene: DAG1; dystroglycan 1

Disease synonyms

cobblestone lissencephaly

LGMD2P

limb-girdle muscular dystrophy

limb-girdle muscular dystrophy-dystroglycanopathy

limb-girdle muscular dystrophy-dystroglycanopathy, type C9

lissencephaly, DAG1-related

lissencephaly type II

MDDGC9

muscular dystrophy-dystroglycanopathy (limb-girdle), type C9

α-dystroglycanopathies

Related Diseases

Related human health report(s)

lissencephaly

muscular dystrophy

muscular dystrophy, limb-girdle, autosomal recessive

muscular dystrophy-dystroglycanopathy

muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9

muscular dystrophy-dystroglycanopathy (limb-girdle), type C9

Ortholog Information

Human gene(s) in FlyBase

Hsap\DAG1

Human gene (HGNC)

Symbol / Name

DAG1; dystroglycan 1

D. melanogaster ortholog (based on DIOPT)

Dmel\Dg

(DIOPT, 2013-)

Comments on ortholog(s)

One to one: 1 human to 1 Drosophila.

Other mammalian ortholog(s) used

D. melanogaster Gene Information (5)

Dmel\Dg

Gene Snapshot

Dystroglycan (Dg) encodes a major non-integrin extracellular matrix (ECM) receptor that connects the ECM to the actin cytoskeleton. It regulates animal survival and temperature preference, muscle integrity, myotendinous and neuromuscular junction formation and function, nervous system development, axon pathfinding, rhabdomere differentiation, neuronal stem cell division and epithelial polarity. [Date last reviewed: 2019-03-07]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

Moderate-scoring ortholog of human DAG1 (1 Drosophila to 1 human). Dmel\Dg shares 23% identity and 36% similarity with the human gene.

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-310

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

Homologous to several human microRNAs, including MIR92A and MIR928 (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-311

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

Homologous to the human microRNA MIR92A (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-312

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

Homologous to several human microRNAs, including MIR92A, MIR928 and MIR25 (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\mir-313

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

Homologous to several human microRNAs, including MIR92A and MIR25 (FBrf0242402).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Other Genes Used: Viral, Bacterial, Synthetic (0)

Summary of Physical Interactions (68 groups)

protein-protein

Interacting group

Assay

References

Dg - α-Spec

anti tag coimmunoprecipitation, western blot

(Bogdanik et al., 2008)

Dg - cora

anti tag coimmunoprecipitation, western blot

(Bogdanik et al., 2008)

Dg - Dys

fluorescence polarization spectroscopy, predetermined participant

(Shcherbata et al., 2007, Yatsenko et al., 2007)

Dg - hts

anti tag coimmunoprecipitation, western blot, Identification by mass spectrometry

(Yatsenko et al., 2020)

Dg - kibra

anti tag coimmunoprecipitation, western blot, Identification by mass spectrometry

(Yatsenko et al., 2020)

Dg - LanA

proximity ligation assay, fluorescence microscopy

(Clayworth and Auld, 2025)

Dg - LanB1

anti tag coimmunoprecipitation, western blot

(Yatsenko et al., 2014)

Dg - LanB2

anti tag coimmunoprecipitation, Identification by mass spectrometry, western blot

(Yatsenko et al., 2020)

Dg - Nrx-1

anti tag coimmunoprecipitation, anti tag western blot

(Zhao et al., 2024)

Dg - rt

anti tag coimmunoprecipitation, anti tag western blot

(Zhao et al., 2024)

Dg - trol

anti bait coimmunoprecipitation, western blot

(Schneider et al., 2006)

Dg - tw

anti tag coimmunoprecipitation, anti tag western blot

(Zhao et al., 2024)

RNA-RNA

Interacting group

Assay

References

Dg - mir-9a

luminiscence technology, immunohistochemistry, quantitative reverse transcription pcr

(Yatsenko and Shcherbata, 2014)

Dg - mir-92a

luminiscence technology

(Yatsenko et al., 2014)

Dg - mir-184

luminiscence technology

(Iovino et al., 2009)

Dg - mir-310

quantitative reverse transcription pcr, immunohistochemistry, luminiscence technology

(Yatsenko et al., 2014)

Dg - mir-311

immunohistochemistry, luminiscence technology, quantitative reverse transcription pcr

(Yatsenko et al., 2014)

Dg - mir-312

quantitative reverse transcription pcr, immunohistochemistry, luminiscence technology

(Yatsenko et al., 2014)

Dg - mir-313

immunohistochemistry, quantitative reverse transcription pcr, luminiscence technology

(Yatsenko et al., 2014)

mir-310

RNA-RNA

Interacting group

Assay

References

mir-310 - arm

western blot, luminiscence technology

(Pancratov et al., 2013)

mir-310 - Cyp6g1

luminiscence technology

(Seong et al., 2020)

mir-310 - Cyp6g2

luminiscence technology

(Seong et al., 2020)

mir-310 - Dg

quantitative reverse transcription pcr, immunohistochemistry, luminiscence technology

(Yatsenko et al., 2014)

mir-310 - Drs

luminiscence technology, quantitative reverse transcription pcr

(Li et al., 2017)

mir-310 - esg

western blot

(Sanchez-Díaz et al., 2015)

mir-310 - Hr96

quantitative reverse transcription pcr, luminiscence technology

(Çiçek et al., 2016)

mir-310 - imd

luminiscence technology

(Li et al., 2024, Robins et al., 2005)

mir-310 - Khc-73

luminiscence technology, necessary binding region, western blot

(Tsurudome et al., 2010)

mir-310 - pan

luminiscence technology

(Pancratov et al., 2013)

mir-310 - Rab23

luminiscence technology, quantitative reverse transcription pcr

(Çiçek et al., 2016)

mir-310 - sha

fluorescence technology

(Schertel et al., 2012)

mir-310 - ttk

quantitative reverse transcription pcr, luminiscence technology

(Çiçek et al., 2016)

RNA-protein

Interacting group

Assay

References

mir-310 - AGO1

anti bait coimmunoprecipitation, northern blot

(Saito et al., 2006)

mir-311

RNA-RNA

Interacting group

Assay

References

mir-311 - arm

luminiscence technology, western blot

(Pancratov et al., 2013)

mir-311 - Cyp6g1

luminiscence technology

(Seong et al., 2020)

mir-311 - Cyp6g2

luminiscence technology

(Seong et al., 2020)

mir-311 - Dg

immunohistochemistry, luminiscence technology, quantitative reverse transcription pcr

(Yatsenko et al., 2014)

mir-311 - Drs

luminiscence technology, quantitative reverse transcription pcr

(Li et al., 2017)

mir-311 - esg

western blot

(Sanchez-Díaz et al., 2015)

mir-311 - Hr96

quantitative reverse transcription pcr, luminiscence technology

(Çiçek et al., 2016)

mir-311 - Khc-73

western blot, luminiscence technology, necessary binding region

(Tsurudome et al., 2010)

mir-311 - pan

luminiscence technology

(Pancratov et al., 2013)

mir-311 - Rab23

luminiscence technology, quantitative reverse transcription pcr

(Çiçek et al., 2016)

mir-311 - sha

fluorescence technology

(Schertel et al., 2012)

mir-311 - ttk

quantitative reverse transcription pcr, luminiscence technology

(Çiçek et al., 2016)

mir-312

RNA-RNA

Interacting group

Assay

References

mir-312 - arm

luminiscence technology, western blot

(Pancratov et al., 2013)

mir-312 - ck

fluorescence technology

(Schertel et al., 2012)

mir-312 - CrebA

luminiscence technology

(Burgler and Macdonald, 2005)

mir-312 - Cyp6g1

luminiscence technology

(Seong et al., 2020)

mir-312 - Cyp6g2

luminiscence technology

(Seong et al., 2020)

mir-312 - Dg

quantitative reverse transcription pcr, immunohistochemistry, luminiscence technology

(Yatsenko et al., 2014)

mir-312 - Drs

quantitative reverse transcription pcr, luminiscence technology

(Li et al., 2017)

mir-312 - esg

western blot

(Sanchez-Díaz et al., 2015)

mir-312 - frtz

fluorescence technology

(Schertel et al., 2012)

mir-312 - Hr96

quantitative reverse transcription pcr, luminiscence technology

(Çiçek et al., 2016)

mir-312 - Khc-73

luminiscence technology, necessary binding region, western blot

(Tsurudome et al., 2010)

mir-312 - pan

luminiscence technology

(Pancratov et al., 2013)

mir-312 - Rab23

luminiscence technology, quantitative reverse transcription pcr

(Çiçek et al., 2016)

mir-312 - sha

fluorescence technology

(Schertel et al., 2012)

mir-312 - ttk

luminiscence technology, quantitative reverse transcription pcr

(Çiçek et al., 2016, Burgler and Macdonald, 2005)

RNA-protein

Interacting group

Assay

References

mir-312 - wisp

enzymatic study, autoradiography

(Lee et al., 2014)

mir-313

RNA-RNA

Interacting group

Assay

References

mir-313 - arm

luminiscence technology, western blot

(Pancratov et al., 2013)

mir-313 - Cyp6g1

luminiscence technology

(Seong et al., 2020)

mir-313 - Cyp6g2

luminiscence technology

(Seong et al., 2020)

mir-313 - Dg

immunohistochemistry, quantitative reverse transcription pcr, luminiscence technology

(Yatsenko et al., 2014)

mir-313 - Drs

quantitative reverse transcription pcr, luminiscence technology

(Li et al., 2017)

mir-313 - esg

western blot

(Sanchez-Díaz et al., 2015)

mir-313 - Hr96

luminiscence technology, quantitative reverse transcription pcr

(Çiçek et al., 2016)

mir-313 - Khc-73

western blot, luminiscence technology, necessary binding region

(Tsurudome et al., 2010)

mir-313 - pan

luminiscence technology

(Pancratov et al., 2013)

mir-313 - Rab23

quantitative reverse transcription pcr, luminiscence technology

(Çiçek et al., 2016)

mir-313 - ttk

luminiscence technology, quantitative reverse transcription pcr

(Çiçek et al., 2016)

Alleles Reported to Model Human Disease (Disease Ontology) (14 alleles)

Models Based on Experimental Evidence ( 7 )

Allele

Disease

Evidence

References

Dg²⁴⁸

model of muscular dystrophy-dystroglycanopathy

CEA with Dg^O86

(Monagas-Valentin et al., 2023)

Dg³²³

model of muscular dystrophy

CEA

(Shcherbata et al., 2007)

Dg^C.UAS

model of muscular dystrophy

CEA

(Yatsenko et al., 2021)

Dg^RNAi.UAS

model of muscular dystrophy

CEA

(Kucherenko et al., 2011, Shcherbata et al., 2007)

Dg^O55

model of muscular dystrophy

CEA with Dg^O86

(Carney et al., 2023, Yatsenko et al., 2021, Marrone et al., 2012, Kucherenko et al., 2011)

Dg^O86

model of muscular dystrophy

CEA with Dg^O55

(Carney et al., 2023, Yatsenko et al., 2021, Marrone et al., 2012, Kucherenko et al., 2011)

CEA

(Yatsenko et al., 2021, Kucherenko et al., 2011, Marrone et al., 2011)

model of muscular dystrophy-dystroglycanopathy

CEA with Dg²⁴⁸

(Monagas-Valentin et al., 2023)

Dg^UAS.cYa

model of lissencephaly

CEA

(Yatsenko et al., 2014)

Modifiers Based on Experimental Evidence ( 5 )

Allele

Disease

Interaction

References

Dg³²³

model of muscular dystrophy

is exacerbated by chif^BG02820a

(Kucherenko et al., 2011)

is exacerbated by Nrk^k14301

(Kucherenko et al., 2011)

is exacerbated by Fhos^A055

(Kucherenko et al., 2011)

is exacerbated by l(2)k09848^EMS-Mod4

(Kucherenko et al., 2011)

is exacerbated by mbl^E27

(Kucherenko et al., 2011)

is exacerbated by Rack1^EY00128

(Kucherenko et al., 2011)

is exacerbated by dysc^c03838

(Kucherenko et al., 2011)

is exacerbated by vimar^k16722

(Kucherenko et al., 2011)

is exacerbated by vimar⁰⁹

(Kucherenko et al., 2011)

is exacerbated by Fkbp14⁰⁰⁷³⁴

(Kucherenko et al., 2011)

is exacerbated by SP2353^MB00605

(Kucherenko et al., 2011)

Dg^RNAi.UAS

model of muscular dystrophy

is exacerbated by Fhos^EY09842

(Kucherenko et al., 2011)

is exacerbated by mbl^E27

(Kucherenko et al., 2011)

is exacerbated by dysc^c03838

(Kucherenko et al., 2011)

is exacerbated by uif^2B7

(Kucherenko et al., 2011)

is exacerbated by chif^EY05746

(Kucherenko et al., 2011)

is exacerbated by Fhos^A055

(Kucherenko et al., 2011)

is exacerbated by l(2)k09848^EMS-Mod4

(Kucherenko et al., 2011)

is exacerbated by vimar^k16722

(Kucherenko et al., 2011)

is exacerbated by vimar⁰⁹

(Kucherenko et al., 2011)

Dg^e01554

exacerbates Walker-Warburg syndrome

modeled by rt^P

(Wairkar et al., 2008)

exacerbates congenital muscular dystrophy-dystroglycanopathy type A1

modeled by rt^P

(Wairkar et al., 2008)

Dg^J43

exacerbates muscular dystrophy-dystroglycanopathy

modeled by rt², rt^EP571

(Monagas-Valentin et al., 2023)

modeled by tw¹

(Monagas-Valentin et al., 2023)

Dg^O86

model of muscular dystrophy

is exacerbated by Sec10^f03085

(Yatsenko et al., 2021)

is exacerbated by Sec15¹

(Yatsenko et al., 2021)

is exacerbated by Sec5^E10

(Yatsenko et al., 2021)

is exacerbated by Sec6^Ex15

(Yatsenko et al., 2021)

is exacerbated by Camⁿ³³⁹

(Marrone et al., 2011)

is exacerbated by Lis-1^k13209

(Kucherenko et al., 2011, Marrone et al., 2011)

is exacerbated by capt^E636

(Marrone et al., 2011)

is ameliorated by chif^BG02820a

(Marrone et al., 2011)

is exacerbated by dysc^GD14018

(Marrone et al., 2011)

is ameliorated by l(2)k09848^EMS-Mod4

(Marrone et al., 2011)

is exacerbated by Nrk^k14301

(Kucherenko et al., 2011)

is exacerbated by chif^BG02820a

(Kucherenko et al., 2011)

is exacerbated by chif^EY05746

(Kucherenko et al., 2011)

is exacerbated by Lis-1^k11702

(Kucherenko et al., 2011)

is exacerbated by Fhos^EY09842

(Kucherenko et al., 2011)

is exacerbated by Itgbn^BG01037

(Kucherenko et al., 2011)

is exacerbated by l(2)k09848^EMS-Mod4

(Kucherenko et al., 2011)

is exacerbated by Rack1^1.8

(Kucherenko et al., 2011)

is exacerbated by mbl^E27

(Kucherenko et al., 2011)

is exacerbated by Rack1^EE

(Kucherenko et al., 2011)

is exacerbated by dysc^c03838

(Kucherenko et al., 2011)

is exacerbated by uif^2B7

(Kucherenko et al., 2011)

is exacerbated by SP2353^MB00605

(Kucherenko et al., 2011)

is exacerbated by uif¹

(Kucherenko et al., 2011)

is exacerbated by Pgk^KG07478

(Kucherenko et al., 2011)

is exacerbated by vimar⁰⁹

(Kucherenko et al., 2011)

is exacerbated by Fkbp14⁰⁰⁷³⁴

(Kucherenko et al., 2011)

exacerbates muscular dystrophy-dystroglycanopathy

modeled by rt², rt^EP571

(Monagas-Valentin et al., 2023)

modeled by tw¹

(Monagas-Valentin et al., 2023)

mir-310

Models Based on Experimental Evidence ( 2 )

Allele

Disease

Evidence

References

mir-310^UAS.pLUC

model of alcohol use disorder

CEA

(Ghezzi et al., 2016)

mir-310^{UAS.cluster.pLUC}

model of alcohol use disorder

CEA with mir-311^{UAS.cluster.pLUC}, mir-312^{UAS.cluster.pLUC}, mir-313^{UAS.cluster.pLUC}

(Ghezzi et al., 2016)

Modifiers Based on Experimental Evidence ( 0 )

Allele

Disease

Interaction

References

mir-311

Models Based on Experimental Evidence ( 1 )

Allele

Disease

Evidence

References

mir-311^{UAS.cluster.pLUC}

model of alcohol use disorder

CEA with mir-310^{UAS.cluster.pLUC}, mir-312^{UAS.cluster.pLUC}, mir-313^{UAS.cluster.pLUC}

(Ghezzi et al., 2016)

Modifiers Based on Experimental Evidence ( 0 )

Allele

Disease

Interaction

References

mir-312

Models Based on Experimental Evidence ( 1 )

Allele

Disease

Evidence

References

mir-312^{UAS.cluster.pLUC}

model of alcohol use disorder

CEA with mir-310^{UAS.cluster.pLUC}, mir-311^{UAS.cluster.pLUC}, mir-313^{UAS.cluster.pLUC}

(Ghezzi et al., 2016)

Modifiers Based on Experimental Evidence ( 0 )

Allele

Disease

Interaction

References

mir-313

Models Based on Experimental Evidence ( 1 )

Allele

Disease

Evidence

References

mir-313^{UAS.cluster.pLUC}

model of alcohol use disorder

CEA with mir-313^{UAS.cluster.pLUC}

(Ghezzi et al., 2016)

Modifiers Based on Experimental Evidence ( 0 )

Allele

Disease

Interaction

References

Alleles Representing Disease-Implicated Variants

Genetic Tools, Stocks and Reagents

Sources of Stocks

Contact lab of origin for a reagent not available from a public stock center.

Bloomington Stock Center Disease Page

Muscular Dystrophies

Related mammalian, viral, bacterial, or synthetic transgenes

Allele

Transgene

Publicly Available Stocks

Hsap\DAG1^UAS.cSa

P{UAS-hDAG1.C}

w¹¹¹⁸; P{UAS-hDAG1.C}2

Selected Drosophila transgenes

Allele

Transgene

Publicly Available Stocks

mir-311^{UAS.cluster.pLUC}

P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}

w¹¹¹⁸; P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}attP2/TM3, Sb¹

mir-310^UAS.pLUC

P{UAS-LUC-mir-310.T}

w¹¹¹⁸; P{UAS-LUC-mir-310.T}attP2/TM3, Sb¹

mir-310^{UAS.cluster.pLUC}

P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}

w¹¹¹⁸; P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}attP2/TM3, Sb¹

mir-313^{UAS.cluster.pLUC}

P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}

w¹¹¹⁸; P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}attP2/TM3, Sb¹

mir-312^{UAS.cluster.pLUC}

P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}

w¹¹¹⁸; P{UAS-LUC-mir-310.mir-311.mir-312.mir-313.T}attP2/TM3, Sb¹

RNAi constructs available

Allele

Transgene

Publicly Available Stocks

y¹ sc^* v¹ sev²¹; P{TRiP.HMS01240}attP2

Dg^VSH330060

P{VSH330060}

P{VSH330060}attP40

Selected Drosophila classical alleles

Allele

Allele class

Mutagen

Publicly Available Stocks

Dg²⁴⁸

Delta2-3 transposase

Dg^e01554

piggyBac activity

Dg³²³

Delta2-3 transposase

Dg^J43

P-element activity

Dg^O55

ethyl methanesulfonate

Dg^O86

ethyl methanesulfonate

y¹ w^*; P{FRT(w^hs)}G13 sha¹ Dg^O86/CyO

References (22)

Report Sections

Open Close